Exelixis (EXEL) Revenue (2010 - 2026)
Exelixis' (EXEL) quarterly Revenue came in at $610.8 million in Q2 2026, up 9.97% year-on-year from $555.4 million in Q2 2025, and up 2.03% quarter-over-quarter from $598.7 million in Q1 2026.
Exelixis (EXEL) Revenue (2010 - 2026) Analysis & Trends
Exelixis' Revenue history runs 17 years deep, the most recent figure standing at $610.8 million for Q2 2026.
- On a quarterly basis, Revenue rose 9.97% year-over-year to $610.8 million in Q2 2026; TTM through Apr 2026 was $2.4 billion, a 3.33% increase from a year earlier, with the FY2026 full-year figure at $2.3 billion, up 6.98% from the prior year.
- Revenue advanced to $610.8 million in Q2 2026 per EXEL's latest filing, from $598.7 million in the prior quarter.
- Across five years, Revenue topped out at $637.2 million in Q2 2024 and bottomed at $356.0 million in Q2 2022.
- The 5-year median for Revenue is $479.7 million (2023), against an average of $502.4 million.
- Across the five-year window, Revenue surged 35.61% in 2024 and slipped 10.82% in 2025, its largest moves.
- Year by year, Revenue stood at $423.9 million in 2022, then rose by 13.15% to $479.7 million in 2023, then grew by 12.49% to $539.5 million in 2024, then grew by 10.79% to $597.8 million in 2025, then rose by 2.18% to $610.8 million in 2026.
- Per Business Quant, the three latest EXEL Revenue figures stand at $610.8 million (Q2 2026), $598.7 million (Q1 2026), and $597.8 million (Q4 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 1.51 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 2.99 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 3.61 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 1.30 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Exelixis | 14.34 Bn | 13.56 Bn | 590.86 Mn | 610.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 610.81 Mn |
| Jan 2, 2026 | 598.66 Mn |
| Oct 3, 2025 | 597.76 Mn |
| Jul 4, 2025 | 568.26 Mn |
| Apr 4, 2025 | 555.45 Mn |
| Jan 3, 2025 | 566.76 Mn |
| Sep 27, 2024 | 539.54 Mn |
| Jun 28, 2024 | 637.18 Mn |
| Mar 29, 2024 | 425.23 Mn |
| Dec 29, 2023 | 479.65 Mn |
| Sep 29, 2023 | 471.92 Mn |
| Jun 30, 2023 | 469.85 Mn |
| Mar 31, 2023 | 408.79 Mn |
| Dec 30, 2022 | 423.92 Mn |
| Sep 30, 2022 | 411.74 Mn |
| Jul 1, 2022 | 419.43 Mn |
| Apr 1, 2022 | 355.98 Mn |
| Oct 1, 2021 | 328.42 Mn |
| Jul 2, 2021 | 385.18 Mn |
| Apr 2, 2021 | 270.23 Mn |